2026-01-13 - Analysis Report
**Financial Report for Merck & Co Inc (MRK)**

**Overview:**
Merck & Co Inc (MRK) is a multinational pharmaceutical company.

**Return Rate Comparison:**
* Cumulative return of review stock: 26.09%
* Cumulative return of comparison stock (S&P 500, VOO): 94.34%
* Divergence (degree of divergence on the last day of the data): -66.40
* Relative divergence (current position within past data): 25.20%

**Alpha, Beta Analysis:**
| Year       | CAGR     | MDD      | Alpha      | Beta      | Cap(B)  |
|------------|----------|----------|------------|------------|---------|
| 2016-2018  | 24.0%    | 14.7%    | 21.0%      | 0.7        | 182.1B  |
| 2017-2019  | 37.0%    | 14.7%    | 20.0%      | 0.7        | 216.8B  |
| 2018-2020  | 13.0%    | 19.3%    | -8.0%      | 0.7        | 195.0B  |
| 2019-2021  | 0.0%     | 19.3%    | -43.0%     | 0.6        | 191.4B  |
| 2020-2022  | 14.0%    | 16.3%    | 16.0%      | 0.5        | 277.1B  |
| 2021-2023  | 31.0%    | 14.3%    | 30.0%      | 0.3        | 272.3B  |
| 2022-2024  | -5.0%    | 24.9%    | -24.0%     | 0.3        | 248.5B  |
| 2023-2025  | -24.0%   | 39.0%    | -86.0%     | 0.3        | 262.9B  |

**Recent Stock Price Fluctuations:**
* Close: $109.19
* Last-market: {'price': 109.19, 'previousClose': 110.53, 'change': -1.21}
* 5-day SMA: $109.64
* 20-day SMA: $105.14
* 60-day SMA: $96.84
* Recent market fluctuation note: sharp decline (-1.21)

**RSI, PPO Index Indicators and Other Analysis:**
* Market Risk Indicator (MRI): 0.80
* RSI: 76.51
* PPO: 0.11
* Recent (20 days) relative divergence change: 1.40 (+): improving
* 7-day Rank change: -3 (-): rank down
* 7-day Dynamic Expected Return change: 0.60 (+): improving
* Expected Return (%): -26.70%
* Expected excess return compared to S&P 500 (if invested long-term): -26.70%

**Recent News & Significant Events:**
* [2026-01-12] Merck (MRK) stock slides as JPMorgan conference tests deal buzz and vaccine risk - TechStock² (news.google.com)
* [2026-01-12] Merck stock rating reiterated at Buy by UBS on cancer drug potential - Investing.com (news.google.com)
* [2025-12-24] Is Merck Stock’s Run Legitimate? - Forbes (news.google.com)
* [2025-12-16] Merck (MRK) Price Target Lifted at Morgan Stanley as Biopharma Outlook Improves - Yahoo Finance (news.google.com)
* [2026-01-09] What Is Happening With Merck Stock? - Trefis (news.google.com)
* [2026-01-12] Merck & Co., Inc. $MRK Shares Sold by Tokio Marine Asset Management Co. Ltd. - MarketBeat (news.google.com)

**Analyst Opinions:**
Analyst Consensus:
* Key: Buy
* Mean (1=StrongBuy~5=Sell): 1.90 (~Buy)
* Opinions: 27
* Target Price (avg/high/low): 113.33 / 135.00 / 83.00

**Recent Earnings Analysis:**
| Date | EPS | Revenue |
|-----|---:|--------|
| 2025-11-05 | 2.32 | 17.28B$ |
| 2025-08-05 | 1.76 | 15.81B$ |
| 2025-05-02 | 2.01 | 15.53B$ |
| 2024-11-06 | 1.25 | 16.66B$ |
| 2025-11-05 | 1.25 | 16.66B$ |

**Revenue and Profitability:**
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $17.28B | 77.69% |
| 2025-06-30 | $15.81B | 77.50% |
| 2025-03-31 | $15.53B | 77.98% |
| 2024-12-31 | $15.62B | 75.50% |
| 2024-09-30 | $16.66B | 75.51% |

**Capital and Profitability:**
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $51.85B | 11.16% |
| 2025-06-30 | $48.99B | 9.04% |
| 2025-03-31 | $48.34B | 10.51% |
| 2024-12-31 | $46.31B | 8.08% |
| 2024-09-30 | $44.50B | 7.09% |

**Comprehensive Analysis (Summary):**
Based on the data, Merck & Co Inc (MRK) has experienced fluctuations in its stock price and return rates. The company's recent news and significant events suggest a mixed sentiment with both positive and negative developments. Analyst opinions indicate a buy recommendation with a moderate target price. Recent earnings analysis shows varying EPS and revenue growth. Revenue and profitability analysis indicates a steady revenue growth with a high profit margin. Capital and profitability analysis shows an increasing equity and ROE. RSI, PPO index indicators, and other analysis suggest a risk level of medium and a low expected return.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.